SCHEMBL23819700

SCHEMBL23819700

O=C1c2ccccc2C(=O)N1[C@H]1CO[C@H](C(=O)O)OC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
TSHR P16473 3/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 2/20 0.40
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
MEN1 O00255 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 3/20 0.36
CHRM2 P08172 1/20 0.36
OPRM1 P35372 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
IKZF3 Q9UKT9 1/20 0.36
CYP1A2 P05177 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
SCN2A Q99250 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619427 1.00 L3MBTL1 (0.43) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL26088195 1.00 L3MBTL1 (0.43) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL29928122 1.00 L3MBTL1 (0.43) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL26086405 0.82 TSHR (0.44) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL23819703 0.82 TSHR (0.44) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL31141354 0.82 TSHR (0.44) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL5316161 0.79 MEN1 (0.42) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL24358382 0.78 L3MBTL1 (0.42) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL26088300 0.77 L3MBTL1 (0.43) L3MBTL1TSHRGAALMNAKMT2A
SCHEMBL26088296 0.77 L3MBTL1 (0.43) L3MBTL1TSHRGAALMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4117780-B1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INT GMBH (DE) 2026-05-06 EP disclosed
US-12441720-B2 Modulators of the integrated stress response pathway EVOTEC INTERNATIONAL GMBH (DE) 2025-10-14 US disclosed
US-20230391763-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2023-12-07 US disclosed
CN-116761803-A Modulators of integrated stress response pathways 埃沃特克国际有限责任公司 2023-09-15 CN disclosed
US-20230129907-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2023-04-27 US disclosed
US-20230129907-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2023-04-27 US disclosed
US-20230129907-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2023-04-27 US disclosed
CN-115190813-A Modulators of integrated stress response pathways 埃沃特克国际有限责任公司 2022-10-14 CN disclosed
WO-2022084447-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2022-04-28 WO disclosed
WO-2021180774-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2021-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391763-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY CRH, AVPR1B, CRHR2 L3MBTL1 1971/4885TSHR 672/4885GAA 3152/4885
US-20230129907-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY CRHR2, CRHR1, CRH L3MBTL1 2133/4885TSHR 621/4885GAA 3158/4885
US-12441720-B2 Modulators of the integrated stress response pathway CRHR2, CRHR1, CRH L3MBTL1 2133/4885TSHR 621/4885GAA 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.